Millennium Predictive Medicine Inc., a spin-off that is taking over the pharmacogenomics and diagnostics applications of Millennium Pharmaceuticals Inc.'s technology platform, now faces the challenges of adding value to the diagnostic segment of the business.

The spin-off announcement last week continues MLNM's strategy to leverage its technology platform while retaining a focus on its core programs, a path the company began discussing early this year and put into practice with the acquisition of ChemGenics Pharmaceuticals Inc. and the spin-out of Millennium BioTherapeutics in May (see BioCentury Extra, Jan. 21, BioCentury, Feb. 10 and BioCentury Extra, May 29).